{"organizations": [], "uuid": "502c6dddaee4057e8522b2bbbed9e1cab65eee1a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-erytech-pharma-selects-triple-nega/brief-erytech-pharma-selects-triple-negative-breast-cancer-as-next-indication-for-eryaspase-idUSFWN1Q301L", "country": "US", "domain_rank": 408, "title": "Erytech Pharma Selects Triple Negative Breast Cancer As Next Indication For Eryaspase​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.358, "site_type": "news", "published": "2018-02-13T14:42:00.000+02:00", "replies_count": 0, "uuid": "502c6dddaee4057e8522b2bbbed9e1cab65eee1a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-erytech-pharma-selects-triple-nega/brief-erytech-pharma-selects-triple-negative-breast-cancer-as-next-indication-for-eryaspase-idUSFWN1Q301L", "ord_in_thread": 0, "title": "Erytech Pharma Selects Triple Negative Breast Cancer As Next Indication For Eryaspase​", "locations": [], "entities": {"persons": [{"name": "erytech", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "erytech pharma", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "eryaspase", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - ERYTECH PHARMA SA:\n* ‍ERYTECH SELECTS TRIPLE NEGATIVE BREAST CANCER AS NEXT INDICATION FOR ERYASPASE​\n* ‍SET-UP ACTIVITIES FOR PHASE 2 CLINICAL STUDY ONGOING, PATIENT ENROLLMENT EXPECTED TO START Q3 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T14:42:00.000+02:00", "crawled": "2018-02-14T12:24:11.034+02:00", "highlightTitle": ""}